Relationship between different level of blood pressure and incidence of cerebral complication in patients with essential hypertension

Abstract

Abstract: AIM: To investigate the relationship between different level of blood pressure and the incidence of cerebral complication in patients with essential hypertensive.METHODS: 696 cases of untreated primary hypertensive patients (387 male and 309 female) were divided into different groups according to the level of systolic blood pressure (SBP), diastolic blood pressure (DBP) and pulse pressure (PP).The relationship between different level of SBP, DBP and PP was analyzed.RESULTS: The incidence of cerebral complication were positively correlated to SBP, DBP and PP (all P < 0.05).The impact ranking was PP >SBP >DBP.CONCLUSION: The cerebral complication in essential hypertension is correlated to SBP, DBP and PP.However, PP plays the most important role among the different parameters of blood pressure in the pathogenesis of the cerebral complication.

Key words: hypertension, systolic blood pressure, diastolic blood pressure, pulse pressure, cerebral complication

CLC Number:

R544.1

CAI Ping, HONG Hua-shan, WANG Yi-bo. Relationship between different level of blood pressure and incidence of cerebral complication in patients with essential hypertension[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2005, 10(9): 1030-1032.

References

1 Mac MM, Sheahan N, Malone JF.Relation between aortic atherosclerosis and blood pressure[J].Lancet, 1994;343: 1107
2 吴兆苏, 姚崇华, 赵冬, 吴桂贤, 王薇, 刘静, 等.中国多省市心血管病趋势及决定因素的人群监测(中国MONICA方案)[J].中华心血管病杂志, 1998;26:85-8
3 Lindenstrom E, Boysen G, Nyboe J.Influence of systolic and diastolic blood pressure on stroke risk:a prospective observational study[J].Am J Epidemiol, 1995;142:1279-90
4 Benetos A, Thomas F, Bean K, Gautier S, Smulyan H, Guize L. Prognostic value of systolic and diastolic blood pressure in treated hypertensive men[J].Arch InternMed, 2002;162:577-81
5 Liu L, Wang JG, Goog L, Liu G, Staessen JA.Comparision of active treatment and placebo in older chinese patients with isolated systolic hypertension[J].J Hypertens, 1998;16:1823-9
6 中国老年高血压临床试验组.中国老年收缩期高血压临床试验总结报告[J].中华心血管病杂志, 1998;26:329-33
7 SHEP Cooperative Research Group.Prevention of stroke by antihypertensive drug treatment in older persons with isoleted systolic hypertension.final results of the systolic hypertension in the elderly program(SHEP)[J].JAMA, 1991;26:3244-55
8 Domanski MJ, Davis BR, Pfeffer MA, Kastantin M, Mitchell GF. Isolated systolic hypertension prognostic information provided by pulse pressure[J].Hypertension, 1999;34:375-80
9 Verdecchia P, Schillaci G, Reboldi G.Different prognostic impact of 24-hour mean blood pressure and pulse pressure on stroke and coronary artery disease in essential hypertention[J]. Circulation, 2001;103:2579-84
10 Kario K, Ishikawa J, Eguchi K, Morinari M, Hoshide S, Ishikawa S, et al.Sleep pulse pressure and awake mean pressure as independent predictors for stroke in older hypertensive patients[J].Am J Hypertens, 2004;17:439-45
11 吴桂贤, 吴兆苏, 刘静, 曾哲淳, 王文化, 秦兰萍, 等.人群脉压分布特征的研究[J].中华心血管病杂志, 2001;29:436-40
12 吴桂贤, 吴兆苏, 秦兰萍, 刘静, 曾哲淳, 王文化, 等.心脑血管病与脉压水平的研究[J].北京医学, 2001;23:202-4
13 王宏宇, 张维忠, 龚兰生, 胡大一.高血压合并动脉粥样硬化与大动脉缓冲功能关系的研究[J].中华心血管病杂志, 2001;29:206-9

[1]	NING Sisi, ZHAO Yuhong, YAN Lei, TANG Minna, ZHANG Ningzhi, ZHANG Yongqiao, CUI Zhaoqiang. Controversies over the targets of controlling blood pressure in hyper- tensive patients with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 463-467.
[2]	SHEN Chang, AI Kelong, HU Changping. Research progress in the regulation of hypoxic pulmonary hypertension by hypoxia-inducible factor-1 signaling pathway [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(1): 114-120.
[3]	FU Hong, TIAN Lei. Individualized precision therapy for patients with ischemic stroke and hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(8): 870-876.
[4]	CHEN Wengang, YIN Qin, ZHANG Weiwei, ZHOU Lulu, KOU Wanqing, YUAN Xiaolong. Distributions of MTHFR gene polymorphism and its correlation with blood Hcy in patients with hypertension in southern Anhui province [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 768-774.
[5]	ZHANG Ningzhi, ZHAO Yuhong, TANG Minna, ZHANG Yongqiao, NING Sisi, CUI Zhaoqiang. Application of chronopharmacology in the hypertension treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 418-422.
[6]	CUI Sumei, CUI Zhaoqiang. Application of β-blockers for hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 423-427.
[7]	LI Yuanfang, CUI Zhaoqiang. Treatment of hypertension complicated with hyperuricemia [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 428-432.
[8]	XU Jianfei, LIN Li. Research progress in pharmacological and non-pharmacological treatments of hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 433-441.
[9]	KUAI Zheng, ZHANG Xiaoyi, ZOU Yunzeng. Angiotensin receptor neprilysin inhibitor in elderly with hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 442-445.
[10]	LIU Guijian, CHENG Kuan, ZHU Wenqing, GE Junbo. Progress of hypertension pharmacological treatment [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(4): 446-449.
[11]	MENG Shi, WANG Zhongqun. Research progress on human immunodeficiency virus-associated pulmonary arterial hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(12): 1431-1440.
[12]	WANG Rui, PAN Jinjin, LI Hua, YUAN Yuhui. Research progress of melatonin on pulmonary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(4): 444-448.
[13]	XING Kai, GONG Jinyu, LUO Jianquan. Advances on pharmacogenomics of diuretics-related adverse reactions [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(2): 204-212.
[14]	YE Peng, TAN Xing, LENG Yueqi, WANG Yangkai, WANG Weizhong. Current opinions and developments of non-pharmacological treatments of hypertension based on sympathetic nervous system [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(12): 1335-1343.
[15]	HU Xiaoyan, XU Qiuping. Application of levosimendan in severe patients after cardiac surgery [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1027-1032.